Reports; Results. Until the end of the Research Term, each Party shall provide written progress reports on the status of its activities under Research Plans during the Collaboration, on a Selected Target-by-Selected Target basis, including detailed summaries of data associated with such activities and, in the case of EPIZYME, reasonably detailed summaries of data generated in the course of its ongoing platform discovery activities to the extent not previously provided to GSK and relevant to the identification or attractiveness for selection of potential Available Targets under Section 2.2, at least [**] Business Days in advance of each JPT meeting.
Appears in 2 contracts
Samples: Collaboration and License Agreement (Epizyme, Inc.), Collaboration and License Agreement (Epizyme, Inc.)
Reports; Results. Until the end of the Research Term, each Each Party shall provide written progress reports on the status of its activities under the Research Plans Plan during the Collaboration, on a an Available Target-by-Available Target or Selected Target-by-Selected Target basis, as applicable, including detailed summaries of data associated with such activities and, in the case of EPIZYME, reasonably detailed summaries of data generated in the course of its ongoing platform discovery activities to the extent not previously provided to GSK CELGENE and relevant to the identification or attractiveness for selection of potential Available Targets under Section 2.22.4.2, at least [**] Business Days in advance of each JPT JRC meeting.
Appears in 2 contracts
Samples: Collaboration and License Agreement (Epizyme, Inc.), Collaboration and License Agreement (Epizyme, Inc.)
Reports; Results. Until the end of the Research TermSubject to Sections 2.3.6 and 2.8.2, each Party shall provide written progress reports on the status of its activities under the Research Plans Plan during the Collaboration, on a Selected an Available Target-by-Selected Target basisAvailable Target, including detailed summaries of data associated with such activities and, in the case of EPIZYME, reasonably detailed summaries of data generated in the course of its ongoing platform discovery activities to the extent not previously provided to GSK CELGENE and relevant to the identification or attractiveness for selection of potential Available Targets under Section 2.22.9.3, at least [**] Business Days in advance of each JPT JRC meeting.
Appears in 1 contract
Samples: Collaboration and License Agreement (Epizyme, Inc.)